Zomedica (ZOM) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 11, 2020
Document Information [Line Items]
Entity Registrant Name	Zomedica Pharmaceuticals Corp.
Entity Central Index Key	0001684144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		166,538,233
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Shares, without par value

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 1,496,752	$ 510,586
Prepaid expenses and deposits	520,290	1,228,585
Tax credits and other receivable	142,463	67,618
Assets, Current, Total	2,159,505	1,806,789
Property and equipment	876,760	729,142
Right-of-use asset	1,499,906	1,103,658
Intangible assets	498,359	543,395
Assets, Total	5,034,530	4,182,984
Current liabilities
Accounts payable and accrued liabilities	1,578,968	2,087,525
Current portion of lease obligations	222,795
Liabilities, Current, Total	1,801,763	2,087,525
Lease obligations	1,281,124
Liabilities, Total	3,082,887	2,087,525
Shareholders' equity
Balance at March 31, 2020	11,961,397	11,961,397
Unlimited common shares without par value; Issued and outstanding 128,871,732 common shares (2019 - 108,038,398)	39,998,442	38,566,820
Additional paid-in capital	4,500,263	3,625,083
Accumulated deficit	(54,508,459)	(52,057,841)
Stockholders' Equity Attributable to Parent, Ending Balance	1,951,643	2,095,459
Liabilities and Equity, Total	$ 5,034,530	$ 4,182,984

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	20	20
Preferred stock, shares issued (in shares)	12	12
Preferred stock, shares outstanding (in shares)	12	12
Capital stock, unlimited common shares	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, shares issued (in shares)	128,871,732	108,038,398
Capital stock, shares outstanding (in shares)	128,871,732	108,038,398

Condensed Unaudited Interim C_3

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Expenses:
Research and development	$ 630,066	$ 7,531,375
General and administrative	1,248,861	3,212,357
Professional fees	290,682	758,298
Amortization - right-of-use asset	42,448	127,345
Accumulated Amortization, Amortization	45,036	267
Depreciation	76,416	62,054
Loss from operations	2,333,509	11,691,696
Interest expense	651	6,174
Loss on disposal of property and equipment	69,834
Loss on right-of-use asset	59,097
Gain on settlement of liabilities		(19,737)
Other income	(5,500)
Foreign exchange gain	(6,973)	(1,225)
Loss before income taxes	2,450,618	11,676,908
Income tax expense
Net loss and comprehensive loss	$ 2,450,618	$ 11,676,908
Weighted average number of common shares (in shares)	118,340,596	100,864,022
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.12)

Condensed Unaudited Interim C_4

Condensed Unaudited Interim Consolidated Statements of Shareholders' (Deficiency) Equity - USD ($)		Preferred Stock [Member]	Common Stock [Member]		Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018			97,598,898
Balance at Dec. 31, 2018			$ 30,410,648		$ 4,280,000	$ 1,240,139	$ (32,273,787)	$ 3,657,000
Stock issued for services (in shares)			707,236	[1],[2]
Stock issued for services			$ 792,104	[1],[2]				792,104
Stock issuance for financing, net of cost (in shares)			9,337,529
Stock issued from financing			$ 6,686,828	[3],[4]	(4,280,000)			2,406,828
Stock-based compensation						2,341,104		$ 2,341,104
Stock issued due to exercise of options (in shares)			394,735					394,735
Stock issued due to exercise of options			$ 754,148			(154,148)		$ 600,000
Net loss							(11,676,908)	(11,676,908)
Balance (in shares) at Mar. 31, 2019			108,038,398
Balance at Mar. 31, 2019			$ 38,643,728			3,427,095	(43,950,695)	(1,879,872)
Balance (in shares) at Dec. 31, 2018			97,598,898
Balance at Dec. 31, 2018			$ 30,410,648		4,280,000	1,240,139	(32,273,787)	3,657,000
Balance (in shares) at Dec. 31, 2019		12	108,038,398
Balance at Dec. 31, 2019		$ 11,961,397	$ 38,566,820			3,625,083	(52,057,841)	2,095,459
Stock issued for services (in shares)			20,833,334
Stock issued for services			$ 1,705,655			794,345		2,500,000
Stock issuance for financing, net of cost (in shares)
Stock issued from financing	[5]		$ 1,431,622
Stock-based compensation						155,022		$ 155,022
Stock issued due to exercise of options (in shares)								0
Net loss							(2,450,618)	$ (2,450,618)
Stock issuance costs			(238,217)			(110,003)		(348,220)
Placement agent warrants			$ (35,816)			35,816
Balance (in shares) at Mar. 31, 2020		12	128,871,732
Balance at Mar. 31, 2020		$ 11,961,397	$ 39,998,442			$ 4,500,263	$ (54,508,459)	$ 1,951,643
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance.
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities.
[3]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock.
[4]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $592,707 of share issuance costs as an offset to common stock.
[5]	On February 14, 2020, the Company completed a registered direct offering ("RDO") of its common shares and a simultaneous private placement of its warrants ("Series A Warrants") in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5.5 years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share ("Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants in addition to 1,041,667 Placement Agent Warrants.

Condensed Unaudited Interim C_5

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows used in operating activities:
Net loss	$ (2,450,618)	$ (11,676,908)
Adjustments for
Depreciation	(76,416)	(62,054)
Amortization - intangible assets	45,036	267
Amortization - right-of-use asset	42,448	127,345
Loss on disposal of property and equipment	69,834
Loss on right-of-use asset	59,097
Non-cash portion of rent expense	4,012
Stock issued for services		792,104
Stock-based compensation	155,022	2,341,104
Change in non-cash operating working capital
Tax and other receivable	(74,845)	(24,313)
Prepaid expenses	11,625	35,591
Deposits	397,403	364,063
Accounts payable and accrued liabilities	(508,557)	5,397,418
Net Cash Provided by (Used in) Operating Activities, Total	(2,173,127)	(2,581,275)
Cash flows from financing activities:
Proceeds from issuance of shares and warrants	2,500,000	3,000,000
Proceeds from stock option exercises		600,000
Stock issuance costs	(348,220)	(593,172)
Net Cash Provided by (Used in) Financing Activities, Total	2,151,780	3,006,828
Cash flows from (used) in investing activities:
Cash from sale of property and equipment	5,400
Investment in property and equipment		(69,087)
Cash from lease repurchase	1,002,113
Net Cash Provided by (Used in) Investing Activities, Total	1,007,513	(69,087)
Increase in cash and cash equivalents	986,166	356,466
Cash and cash equivalents, beginning of period	510,586	1,940,265
Cash and cash equivalents, end of period	1,496,752	2,296,731
Supplemental cash flows information:
Interest paid	$ 651	$ 6,174

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Going Concern	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Nature of operations and going concern Zomedica Pharmaceuticals Corp. ("Zomedica" or the “Company”) was incorporated on January 7, 2013 Business Corporations Act 2.4 May 14, 2015 On April 21, 2016, three 9674128 one 2.5 2.4 Capital Pool Companies May 2, 2016. June 21, 2016, Zomedica has one 100 180, 48108 3400, 350 7 th T2P 3N9. On November 20, 2017, 1 November 21, 2017, Going concern The consolidated financial statements are prepared on a going concern basis, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve $54,508,459 March 31, 2020 ( December 31, 2019 - $52,057,841 no In order for the Company to continue as a going concern and fund any significant expansion of its operation or R&D activities, the Company will require significant additional capital. The Company’s ultimate success will depend on whether its future product candidates receive the necessary regulatory approval and it is able to successfully market approved products. The Company cannot be certain that it will be able to receive regulatory approval, if required, for any of its future product candidates, if required, or that it will reach the level of sales and revenues necessary to achieve and sustain profitability. The availability of equity or debt financing will be affected by, among other things, the results of the Company’s research and development, its ability to obtain regulatory approvals, the market acceptance of its products, the state of the capital markets generally, and due to the emergence of the COVID- 19 may not no not not

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. The condensed unaudited interim consolidated financial statements do not December 31, 2019. three March 31, 2020 not may December 31, 2020. These condensed unaudited interim consolidated financial statements were prepared using the same basis of presentation, accounting policies and methods of computation as those of the audited consolidated financial statements for the year ended December 31, 2019. Basis of consolidation These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc. All inter-company accounts and transactions have been eliminated on consolidation.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption. Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements. Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock. Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are remeasured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three March 31, 2020 Comprehensive loss The Company follows ASC topic 220. no

Note 4 - Critical Accounting Ju

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not may The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Going concern These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due. Stock-based payments The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends. Useful lives of property and equipment The Company reviews the estimated useful lives of property and equipment with definite useful lives at the end of each year and assesses whether the useful lives of certain items should be shortened or extended, due to various factors including technology, competition and revised service offerings. During the three March 31, 2020 2019, not may not The impact of the novel strain of coronavirus (“COVID- 19” Since December 31, 2019, 19”, March 2020.

Note 5 - Prepaid Expenses, Depo

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Prepaid Rent [Text Block]	5. Prepaid expenses, deposits and deferred financing costs March 31, December 31, 2020 2019 Deposits (i) $ 336,560 $ 1,033,231 Prepaid marketing (ii) 15,459 19,829 Prepaid insurance (ii) 65,249 110,636 Other (iii) 103,022 64,889 Total $ 520,290 $ 1,228,585 (i) Deposits include payments made to vendors in advance and are primarily associated with research activity, leasing deposits and costs for additional office space. As of March 31, 2020, December 31, 2019, (ii) As of March 31, 2020, December 31, 2019, (iii) Other is comprised of deferred financing costs, subscription payments, utilities, travel costs and software licensing. As of March 31, 2020, December 31, 2019,

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment Computer Furniture and Laboratory Leasehold Total Cost Balance at December 31, 2018 $ 170,002 $ 181,879 $ 352,637 $ 282,975 $ 987,493 Additions 218,076 3,415 3,350 65,672 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at December 31, 2019 385,868 185,294 355,987 348,647 1,275,796 Additions - - - 299,268 299,268 Disposals (9,933 ) (64,018 ) (13,712 ) (76,455 ) (164,117 ) Balance at March 31, 2020 375,935 121,276 342,275 571,460 1,410,947 Accumulated depreciation Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 88,417 26,617 68,519 93,597 277,149 Disposals (901 ) - - - (901 ) Balance at December 31, 2019 192,434 56,202 168,215 129,803 546,653 Depreciation 22,704 4,421 17,297 31,994 76,416 Disposals (2,849 ) (28,505 ) (30,843 ) (26,686 ) (88,883 ) Balance at March 31, 2020 212,289 32,118 154,669 135,111 534,186 Net book value as at: December 31, 2019 $ 193,434 $ 129,092 $ 187,772 $ 218,844 $ 729,142 March 31, 2020 $ 163,648 $ 89,157 $ 187,606 $ 436,349 $ 876,760 In February 2020, $75,234. $5,400 $69,834 During the three March 31, 2020, $299,268 February 2020, 2019.

Note 7 - Intangible Assets

Note 7 - Intangible Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible assets Computer Trademarks Website Total intangible Cost Balance at December 31, 2018 $ 5,143 $ 16,236 $ - $ 21,379 Additions - - 531,419 531,419 Balance at December 31, 2019 5,143 16,236 531,419 552,798 Additions - - - - Balance at March 31, 2020 5,143 16,236 531,419 552,798 Accumulated amortization Balance at December 31, 2018 5,143 3,178 - 8,321 Amortization - 1,082 - 1,082 Balance at December 31, 2019 5,143 4,260 - 9,403 Amortization - 272 44,764 45,036 Balance at March 31, 2020 5,143 4,532 44,764 54,439 Net book value as at: December 31, 2019 $ - $ 11,975 $ 531,419 $ 543,395 March 31, 2020 $ - $ 11,704 $ 486,655 $ 498,359 Total estimated future amortization of intangible assets for each fiscal year is as follows: 2020 $ 134,804 2021 180,144 2022 180,144 2023 1,089 2024 1,089 2025 1,089 Total $ 498,359

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases The Company adopted ASC 842 January 1, 2019. two January 1, 2019, $1,613,038 $42,448 three March 31, 2020 ( March 31, 2019 - $127,345 On February 1, 2020 60 February 1, 2020 January 31, 2025 $32,452 $36,525 $1,002,113. $1,061,210 $59,097 On February 1, 2020, $1,553,611 12%. During the three March 31, 2020, $68,917 February 1, 2020 $17,229 $51,687 three March 31, 2020, $4,331 Right-of-use asset Premise lease Cost Aggregate lease commitments $ 2,067,505 Less: impact of present value (513,894 ) Balance at March 31, 2020 1,553,611 Reduction in right-of-use asset Straight line amortization 68,917 Interest (15,212 ) Balance at March 31, 2020 53,705 Net book value as at: March 31, 2020 $ 1,499,906 Lease liabilities Premise lease Additions $ 1,553,611 Payments (64,904 ) Interest 15,212 Total lease liabilities at March 31, 2020 1,503,919 Current portion of lease liabilities 222,795 Long term portion of lease liabilities 1,281,124 Total lease liabilities at March 31, 2020 $ 1,503,919 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2020 $ 292,068 2021 400,133 2022 412,137 2023 424,501 2024 437,236 2025 36,525 Total $ 2,002,600

Note 9 - Loan Arrangements

Note 9 - Loan Arrangements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	9. Loan arrangements On October 18, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% March 31, 2020, no

Note 10 - Preferred Stock

Note 10 - Preferred Stock	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred stock The Company is authorized to issue up to 20 1 $1,000,000. 1 not not 1 not 9 9 1 1 9 1 Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of Series 1 1 1 In the event of a fundamental transaction (defined to include an amalgamation, merger or other business combination transaction involving our company in which our shareholders do not 50% may third 1 1 1 5.0 9.0 1 Issued and outstanding preferred stock: Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,961,397 Balance at December 31, 2019 12 11,961,397 Balance at March 31, 2020 12 $ 11,961,397 (i) On May 9, 2019, $12,000,000 1 $1,000,000 1 $5,000,000 May 9, 2019 $7,000,000 June 7, 2019. $38,603 December 31, 2019.

Note 11 - Common Stock

Note 11 - Common Stock	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common stock The Company is authorized to issue an unlimited number of shares of common stock, all without par value. Issued and outstanding common stock: Number of Common Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issued for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,686,828 Stock issued due to exercise of options 394,735 754,148 Balance at March 31, 2019 108,038,398 $ 38,643,728 Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (v) 20,833,334 1,431,622 Balance at March 31, 2020 128,871,732 $ 39,998,442 (i) On January 14, 2019, $75,000 49,342 $55,263 $19,737 (ii) On January 14, 2019, 657,894 $1,000,000 third $736,841 (iii) On January 14, 2019, 2,815,789 $4,280,000 December 31, 2018.The $465 (iv) On March 28, 2019, 6,521,740 $3,000,000. $592,707 (v) On February 14, 2020, one one 20,833,334 20,833,334 $0.12 $0.20 six 5.5 1,041,667 $0.15 5 20,833,334 20,833,334 1,041,667 The Company raised $2,500,000 $1,705,655 $794,345 The direct cash costs related to the issuance of the common shares and warrants issued in February $348,220. $238,217 $110,003 $52,496 $35,816 $16,680

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Stock-based compensation During the three March 31, 2020, 5,056,000 one three five three March 31, 2020, nil three March 31, 2019, 5,995,000 one two three March 31, 2019, 394,735 The continuity of stock options are as follows: Number of Weighted Avg Exercise Price Balance at December 31, 2019 7,040,265 $ 1.28 Stock options forfeited January 23, 2020 (50,000 ) $ 1.52 Stock options forfeited February 25, 2020 (5,000 ) $ 1.52 Stock options forfeited March 1, 2020 (50,000 ) $ 1.52 Stock options granted March 14,2020 5,056,000 $ 0.19 Balance at March 31, 2020 11,991,265 $ 0.82 Vested at March 31, 2020 8,199,265 $ 1.11 As at March 31, 2020, Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 $ 1.52 5,390,265 5,390,265 - 0.78 January 10, 2019 1.52 15,000 15,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 August 19, 2019 0.26 500,000 500,000 - 1.39 August 19, 2019 0.35 100,000 100,000 - 1.39 August 19, 2019 0.45 100,000 100,000 - 1.39 August 19, 2019 0.55 100,000 100,000 - 1.39 August 19, 2019 0.65 100,000 100,000 - 1.39 August 19, 2019 0.75 100,000 100,000 - 1.39 September 16, 2019 0.43 500,000 500,000 - 1.46 March 14, 2020 0.19 5,056,000 1,264,000 3,792,000 4.96 Balance at March 31, 2020 11,991,265 8,199,265 3,792,000 The fair value of options granted during the three March 31, 2020 March 31, 2019 March 14, 2020 January 10, 2019 Volatility 87% 68% Risk-free interest rate 0.49% 2.56% Expected life (years) 5 2 Divedend yield 0% 0% Common share price $0.18 $1.23 Strike price $0.19 $1.52 Forfeiture rate nil nil The Company recorded $155,022 three March 31, 2020 ( 2019 $2,341,104 three March 31, 2019 $600,000 $154,148 The Company has estimated its stock option forfeitures to be nil three March 31, 2020 ( three March 31, 2019 - nil

Note 13 - Warrants

Note 13 - Warrants	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Warrants Note Disclosure [Text Block]	13. Warrants In connection with the February 14, 2020 20,833,334 five one one $.20. 1,041,667 $0.15 As at March 31, 2020, Original Issue date Exercise Warrants Weighted Average February 14, 2020 0.20 20,833,334 5.38 February 14, 2020 0.15 1,041,667 4.87 Balance at March 31, 2020 21,875,001 The fair value of warrants issued the three March 31, 2020 Series A Warrants Placement Agent Warrants Volatility 87% 87% Risk-free interest rate 1.42% 1.42% Expected life (years) 5.5 5 Dividend yield 0% 0% Common share price $0.12 $0.12 Strike price $0.20 $0.15 Forfeiture rate nil nil

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and contingencies On November 26, 2018, • 1 st March 15, 2019 - $2,000,000 • 2 nd March 15, 2019, ° $3,000,000 or ° $1,500,000 $1.95 • 3 rd September 12, 2019, ° $3,000,000 or ° $1,500,000 $1.95 • 4 th February 19, 2020 - $2,000,000 As at March 31, 2020, first second third April 2020. $3,000,000 fourth not On May 10, 2018, • $3,500,000 • $3,500,000 10 As at March 31, 2020, none From time to time, the Company may March 31, 2020, May 11, 2020, not On November 1, 2019, 1:19 01108 TM January 21, 2020, February 11, 2020, February 25, 2020. not no not TM 2020, 19, Under the terms of the Development and Supply Agreement, dated November 26, 2018, third

Note 15 - Financial Instruments

Note 15 - Financial Instruments	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	15. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates expected volatility based on historical volatility of the Company’s stock price. When there is insufficient data available, The Company uses a peer group that is publicly traded to calculate expected volatility. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not (c) Foreign exchange risk The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at March 31, 2020 December 31, 2019: March 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,578,968 - - - - 1,578,968 1,578,968 - - - - 1,578,968 December 31, 2019 Less than 3 to 6 6 to 9 9 months Greater than Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,087,525 - - - - 2,087,525 2,087,525 - - - - 2,087,525

Note 16 - Segmented Information

Note 16 - Segmented Information	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	16. Segmented information The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion animal. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all the Company's long-lived assets are in the United States of America (“US”). March 31, December 31, 2020 2019 $ $ Total assets Canada 312,420 249,929 US 4,722,110 3,933,055 Total US property and equipment 876,760 729,142 Total US right-of-use asset 1,499,906 1,103,658 2,376,666 1,832,800

Note 17 - Schedule of Expenses

Note 17 - Schedule of Expenses	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Operating Expenses [Text Block]	17. Schedule of expenses For the three months ended March 31, 2020 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 212,143 $ - $ 751,389 Contracted expenditures 362,868 - - Marketing and investor relations - - 49,552 Travel and accommodation 454 - 12,474 Insurance 239 - 46,031 Office 22,656 - 244,929 Consultants 2,976 290,682 - Regulatory - - 88,468 Rent 17,229 - 56,018 Supplies 11,501 - - Total $ 630,066 $ 290,682 $ 1,248,861 For the three months ended March 31, 2019 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 245,307 $ - $ 2,972,172 Contracted expenditures 1,254,847 - - Marketing and investor relations - - 52,509 Travel and accommodation 10,049 - 57,264 Insurance 1,466 - 20,781 License fees 5,886,841 - - Office 6,428 - 67,243 Consultants 59,786 758,298 - Regulatory 20,998 - 24,104 Rent - - 5,940 Supplies 45,653 - 12,344 Total $ 7,531,375 $ 758,298 $ 3,212,357

Note 18 - Capital Risk Manageme

Note 18 - Capital Risk Management	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Capital Risk Management [Text Block]	18. Capital risk management The capital of the Company includes equity, which is comprised of issued common capital stock, preferred stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

Note 19 - Loss Per Share

Note 19 - Loss Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	19. Loss per share For the three months For the three months Numerator Net loss for the period $ 2,450,618 $ 11,676,908 Denominator Weighted average shares - basic 118,340,596 100,864,022 Stock options - - Warrants - - Denominator for diluted loss per share 118,340,596 100,864,022 Loss per share - basic and diluted $ (0.02 ) $ (0.12 ) For the above-mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive. The Company excluded 11,991,265 21,875,001

Note 20 - Related Party Transac

Note 20 - Related Party Transactions and Key Management Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	20. Related party transactions and key management compensation Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows: For the three months For the three months Salaries and benefits, including bonuses $ 156,536 $ 320,647 Stock-based compensation 99,613 1,644,325 Total $ 256,149 $ 1,964,972

Note 21 - Subsequent Events

Note 21 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	21. On April 9, 2020, $4,000,000 one 0.5 $0.12 33,333,334 16,666,667 $0.15 5 $4,000,000. As of May 11, 2020, $649,870 4,333,167 On April 3, 2020, 19 · The loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over the 8 · Employee and compensation levels are maintained. Payroll costs are capped at $100,000 not 25% may 6 April 20, 2020 $527,360.

Note 22 - Comparative Figures

Note 22 - Comparative Figures	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Reclassifications [Text Block]	22. Comparative figures Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no March 31, 2019, not

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.
Basis of Measurement [Policy Text Block]	Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Functional and Reporting Currencies [Policy Text Block]	Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Share Issue Costs [Policy Text Block]	Share issue costs Share issue costs are recorded as a reduction of the proceeds from the issuance of capital stock.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are remeasured at the period end rates. Revenue and expenses are remeasured at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option using the graded vesting method. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options is excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not three March 31, 2020
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss The Company follows ASC topic 220. no

Note 5 - Prepaid Expenses, De_2

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Prepaid Expenses and Deposits [Table Text Block]	March 31, December 31, 2020 2019 Deposits (i) $ 336,560 $ 1,033,231 Prepaid marketing (ii) 15,459 19,829 Prepaid insurance (ii) 65,249 110,636 Other (iii) 103,022 64,889 Total $ 520,290 $ 1,228,585

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer Furniture and Laboratory Leasehold Total Cost Balance at December 31, 2018 $ 170,002 $ 181,879 $ 352,637 $ 282,975 $ 987,493 Additions 218,076 3,415 3,350 65,672 290,513 Disposals (2,210 ) - - - (2,210 ) Balance at December 31, 2019 385,868 185,294 355,987 348,647 1,275,796 Additions - - - 299,268 299,268 Disposals (9,933 ) (64,018 ) (13,712 ) (76,455 ) (164,117 ) Balance at March 31, 2020 375,935 121,276 342,275 571,460 1,410,947 Accumulated depreciation Balance at December 31, 2018 104,918 29,585 99,696 36,206 270,405 Depreciation 88,417 26,617 68,519 93,597 277,149 Disposals (901 ) - - - (901 ) Balance at December 31, 2019 192,434 56,202 168,215 129,803 546,653 Depreciation 22,704 4,421 17,297 31,994 76,416 Disposals (2,849 ) (28,505 ) (30,843 ) (26,686 ) (88,883 ) Balance at March 31, 2020 212,289 32,118 154,669 135,111 534,186 Net book value as at: December 31, 2019 $ 193,434 $ 129,092 $ 187,772 $ 218,844 $ 729,142 March 31, 2020 $ 163,648 $ 89,157 $ 187,606 $ 436,349 $ 876,760

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Computer Trademarks Website Total intangible Cost Balance at December 31, 2018 $ 5,143 $ 16,236 $ - $ 21,379 Additions - - 531,419 531,419 Balance at December 31, 2019 5,143 16,236 531,419 552,798 Additions - - - - Balance at March 31, 2020 5,143 16,236 531,419 552,798 Accumulated amortization Balance at December 31, 2018 5,143 3,178 - 8,321 Amortization - 1,082 - 1,082 Balance at December 31, 2019 5,143 4,260 - 9,403 Amortization - 272 44,764 45,036 Balance at March 31, 2020 5,143 4,532 44,764 54,439 Net book value as at: December 31, 2019 $ - $ 11,975 $ 531,419 $ 543,395 March 31, 2020 $ - $ 11,704 $ 486,655 $ 498,359
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2020 $ 134,804 2021 180,144 2022 180,144 2023 1,089 2024 1,089 2025 1,089 Total $ 498,359

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lessee, Operating Lease, Right of Use Asset and Lease Liabilities [Table Text Block]	Right-of-use asset Premise lease Cost Aggregate lease commitments $ 2,067,505 Less: impact of present value (513,894 ) Balance at March 31, 2020 1,553,611 Reduction in right-of-use asset Straight line amortization 68,917 Interest (15,212 ) Balance at March 31, 2020 53,705 Net book value as at: March 31, 2020 $ 1,499,906 Lease liabilities Premise lease Additions $ 1,553,611 Payments (64,904 ) Interest 15,212 Total lease liabilities at March 31, 2020 1,503,919 Current portion of lease liabilities 222,795 Long term portion of lease liabilities 1,281,124 Total lease liabilities at March 31, 2020 $ 1,503,919 Total remaining undiscounted lease liabilities related to the above lease are as follows: 2020 $ 292,068 2021 400,133 2022 412,137 2023 424,501 2024 437,236 2025 36,525 Total $ 2,002,600

Note 10 - Preferred Stock (Tabl

Note 10 - Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	Number of preferred Preferred stock stock amount Balance at December 31, 2018 - $ - Stock issued from financing (i) 12 11,961,397 Balance at December 31, 2019 12 11,961,397 Balance at March 31, 2020 12 $ 11,961,397

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Number of Common Balance at December 31, 2018 97,598,898 $ 30,410,648 Stock issued for services (i and ii) 707,236 792,104 Stock issued from financing (iii and iv) 9,337,529 6,686,828 Stock issued due to exercise of options 394,735 754,148 Balance at March 31, 2019 108,038,398 $ 38,643,728 Balance at December 31, 2019 108,038,398 $ 38,566,820 Stock issued from financing (v) 20,833,334 1,431,622 Balance at March 31, 2020 128,871,732 $ 39,998,442

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted Avg Exercise Price Balance at December 31, 2019 7,040,265 $ 1.28 Stock options forfeited January 23, 2020 (50,000 ) $ 1.52 Stock options forfeited February 25, 2020 (5,000 ) $ 1.52 Stock options forfeited March 1, 2020 (50,000 ) $ 1.52 Stock options granted March 14,2020 5,056,000 $ 0.19 Balance at March 31, 2020 11,991,265 $ 0.82 Vested at March 31, 2020 8,199,265 $ 1.11
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price Number of options issued and outstanding Number of vested options outstanding Number of unvested options outstanding Weighted Avg Remaining Life outstanding (years) January 10, 2019 $ 1.52 5,390,265 5,390,265 - 0.78 January 10, 2019 1.52 15,000 15,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 January 10, 2019 1.52 10,000 10,000 - 0.10 August 19, 2019 0.26 500,000 500,000 - 1.39 August 19, 2019 0.35 100,000 100,000 - 1.39 August 19, 2019 0.45 100,000 100,000 - 1.39 August 19, 2019 0.55 100,000 100,000 - 1.39 August 19, 2019 0.65 100,000 100,000 - 1.39 August 19, 2019 0.75 100,000 100,000 - 1.39 September 16, 2019 0.43 500,000 500,000 - 1.46 March 14, 2020 0.19 5,056,000 1,264,000 3,792,000 4.96 Balance at March 31, 2020 11,991,265 8,199,265 3,792,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	March 14, 2020 January 10, 2019 Volatility 87% 68% Risk-free interest rate 0.49% 2.56% Expected life (years) 5 2 Divedend yield 0% 0% Common share price $0.18 $1.23 Strike price $0.19 $1.52 Forfeiture rate nil nil

Note 13 - Warrants (Tables)

Note 13 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Original Issue date Exercise Warrants Weighted Average February 14, 2020 0.20 20,833,334 5.38 February 14, 2020 0.15 1,041,667 4.87 Balance at March 31, 2020 21,875,001
Schedule of Warrant or Right Outstanding and Options, Valuation Assumptions [Table Text Block]	Series A Warrants Placement Agent Warrants Volatility 87% 87% Risk-free interest rate 1.42% 1.42% Expected life (years) 5.5 5 Dividend yield 0% 0% Common share price $0.12 $0.12 Strike price $0.20 $0.15 Forfeiture rate nil nil

Note 15 - Financial Instrumen_2

Note 15 - Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	March 31, 2020 Less than 3 to 6 6 to 9 9 months Greater than Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,578,968 - - - - 1,578,968 1,578,968 - - - - 1,578,968 December 31, 2019 Less than 3 to 6 6 to 9 9 months Greater than Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 2,087,525 - - - - 2,087,525 2,087,525 - - - - 2,087,525

Note 16 - Segmented Informati_2

Note 16 - Segmented Information (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	March 31, December 31, 2020 2019 $ $ Total assets Canada 312,420 249,929 US 4,722,110 3,933,055 Total US property and equipment 876,760 729,142 Total US right-of-use asset 1,499,906 1,103,658 2,376,666 1,832,800

Note 17 - Schedule of Expenses

Note 17 - Schedule of Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Operating Expenses [Table Text Block]	For the three months ended March 31, 2020 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 212,143 $ - $ 751,389 Contracted expenditures 362,868 - - Marketing and investor relations - - 49,552 Travel and accommodation 454 - 12,474 Insurance 239 - 46,031 Office 22,656 - 244,929 Consultants 2,976 290,682 - Regulatory - - 88,468 Rent 17,229 - 56,018 Supplies 11,501 - - Total $ 630,066 $ 290,682 $ 1,248,861 For the three months ended March 31, 2019 Research and Professional General and Development Fees Administrative Salaries, bonus and benefits $ 245,307 $ - $ 2,972,172 Contracted expenditures 1,254,847 - - Marketing and investor relations - - 52,509 Travel and accommodation 10,049 - 57,264 Insurance 1,466 - 20,781 License fees 5,886,841 - - Office 6,428 - 67,243 Consultants 59,786 758,298 - Regulatory 20,998 - 24,104 Rent - - 5,940 Supplies 45,653 - 12,344 Total $ 7,531,375 $ 758,298 $ 3,212,357

Note 19 - Loss Per Share (Table

Note 19 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months For the three months Numerator Net loss for the period $ 2,450,618 $ 11,676,908 Denominator Weighted average shares - basic 118,340,596 100,864,022 Stock options - - Warrants - - Denominator for diluted loss per share 118,340,596 100,864,022 Loss per share - basic and diluted $ (0.02 ) $ (0.12 )

Note 20 - Related Party Trans_2

Note 20 - Related Party Transactions and Key Management Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Key Management Personnel Compensation [Table Text Block]	For the three months For the three months Salaries and benefits, including bonuses $ 156,536 $ 320,647 Stock-based compensation 99,613 1,644,325 Total $ 256,149 $ 1,964,972

Note 1 - Nature of Operations_2

Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (54,508,459)	$ (52,057,841)

Note 5 - Prepaid Expenses, De_3

Note 5 - Prepaid Expenses, Deposits and Deferred Financing Costs - Summary of Prepaid Expenses and Deposits (Details) - USD ($)		Mar. 31, 2020	Dec. 31, 2019
Deposits	[1]	$ 336,560	$ 1,033,231
Prepaid marketing	[2]	15,459	19,829
Prepaid insurance	[2]	65,249	110,636
Other	[3]	103,022	64,889
Total		$ 520,290	$ 1,228,585
[1]	Deposits include payments made to vendors in advance and are primarily associated with research activity, leasing deposits and costs for additional office space. As of March 31, 2020, and December 31, 2019, the Company classified all amounts as a current asset in the consolidated balance sheet, respectively;
[2]	As of March 31, 2020, and December 31, 2019, all amounts were classified as a current asset in the consolidated balance sheet;
[3]	Other is comprised of deferred financing costs, subscription payments, utilities, travel costs and software licensing. As of March 31, 2020, and December 31, 2019, the Company classified all amounts as a current asset in the consolidated balance sheet.

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($)	1 Months Ended
	Feb. 29, 2020	Mar. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment, Net, Ending Balance	$ 75,234	$ 876,760	$ 729,142
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset	5,400
Gain (Loss) on Disposition of Property Plant Equipment, Total	$ (69,834)
Reclassification of Prepaid Expenses to Leasehold Improvements [Member]
Prepaid Expense		(299,268)
Leasehold Improvements [Member]
Property, Plant and Equipment, Net, Ending Balance		436,349	$ 218,844
Leasehold Improvements [Member] | Reclassification of Prepaid Expenses to Leasehold Improvements [Member]
Property, Plant and Equipment, Net, Ending Balance		$ 299,268

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Feb. 29, 2020
Cost, Beginning Balance	$ 1,275,796	$ 987,493
Cost, Additions	299,268	290,513
Cost, Disposals	(164,117)	(2,210)
Cost, Ending Balance	1,410,947	1,275,796
Accumulated Depreciation, Beginning Balance	546,653	270,405
Accumulated Depreciation, Depreciation	76,416	277,149
Accumulated Depreciation, Disposals	(88,883)	(901)
Accumulated Depreciation, Ending Balance	534,186	546,653
Property, Plant and Equipment, Net, Ending Balance	876,760	729,142	$ 75,234
Computer Equipment [Member]
Cost, Beginning Balance	385,868	170,002
Cost, Additions		218,076
Cost, Disposals	(9,933)	(2,210)
Cost, Ending Balance	375,935	385,868
Accumulated Depreciation, Beginning Balance	192,434	104,918
Accumulated Depreciation, Depreciation	22,704	88,417
Accumulated Depreciation, Disposals	(2,849)	(901)
Accumulated Depreciation, Ending Balance	212,289	192,434
Property, Plant and Equipment, Net, Ending Balance	163,648	193,434
Furniture and Fixtures [Member]
Cost, Beginning Balance	185,294	181,879
Cost, Additions		3,415
Cost, Disposals	(64,018)
Cost, Ending Balance	121,276	185,294
Accumulated Depreciation, Beginning Balance	56,202	29,585
Accumulated Depreciation, Depreciation	4,421	26,617
Accumulated Depreciation, Disposals	(28,505)
Accumulated Depreciation, Ending Balance	32,118	56,202
Property, Plant and Equipment, Net, Ending Balance	89,157	129,092
Laboratory Equipment [Member]
Cost, Beginning Balance	355,987	352,637
Cost, Additions		3,350
Cost, Disposals	(13,712)
Cost, Ending Balance	342,275	355,987
Accumulated Depreciation, Beginning Balance	168,215	99,696
Accumulated Depreciation, Depreciation	17,297	68,519
Accumulated Depreciation, Disposals	(30,843)
Accumulated Depreciation, Ending Balance	154,669	168,215
Property, Plant and Equipment, Net, Ending Balance	187,606	187,772
Leasehold Improvements [Member]
Cost, Beginning Balance	348,647	282,975
Cost, Additions	299,268	65,672
Cost, Disposals	(76,455)
Cost, Ending Balance	571,460	348,647
Accumulated Depreciation, Beginning Balance	129,803	36,206
Accumulated Depreciation, Depreciation	31,994	93,597
Accumulated Depreciation, Disposals	(26,686)
Accumulated Depreciation, Ending Balance	135,111	129,803
Property, Plant and Equipment, Net, Ending Balance	$ 436,349	$ 218,844

Note 7 - Intangible Assets - Fi

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Cost, Beginning Balance	$ 552,798	$ 21,379	$ 21,379
Cost, Additions			531,419
Cost, Ending Balance	552,798		552,798
Accumulated Amortization, Beginning Balance	9,403	8,321	8,321
Accumulated Amortization, Amortization	45,036	267	1,082
Accumulated Amortization, Ending Balance	54,439		9,403
Net Book Value	498,359		543,395
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance	5,143	5,143	5,143
Cost, Additions
Cost, Ending Balance	5,143		5,143
Accumulated Amortization, Beginning Balance	5,143	5,143	5,143
Accumulated Amortization, Amortization
Accumulated Amortization, Ending Balance	5,143		5,143
Net Book Value
Trademarks [Member]
Cost, Beginning Balance	16,236	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236		16,236
Accumulated Amortization, Beginning Balance	4,260	3,178	3,178
Accumulated Amortization, Amortization	272		1,082
Accumulated Amortization, Ending Balance	4,532		4,260
Net Book Value	11,704		11,975
Website [Member]
Cost, Beginning Balance	531,419
Cost, Additions			531,419
Cost, Ending Balance	531,419		531,419
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Amortization	44,764
Accumulated Amortization, Ending Balance	44,764
Net Book Value	$ 486,655		$ 531,419

Note 7 - Intangible Assets - Es

Note 7 - Intangible Assets - Estimated Future Amortization of Intangible (Details)	Mar. 31, 2020USD ($)
2020	$ 134,804
2021	180,144
2022	180,144
2023	1,089
2024	1,089
2025	1,089
Total	$ 498,359

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	Feb. 01, 2020USD ($)	Jan. 01, 2019USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Number of Lease Agreements					2
Operating Lease, Right-of-Use Asset, Amortization Expense			$ 42,448	$ 127,345
Increase (Decrease) in Prepaid Rent			1,002,113
Operating Lease, Impairment Loss			59,097
Operating Lease, Right-of-Use Asset			1,499,906		$ 1,103,658
Operating Lease, Liability, Total			1,503,919
General and Administrative Expense [Member]
Operating Lease, Expense			4,331
Lease Agreement with Wickfield Phoenix LLC [Member]
Lessee, Operating Lease, Term of Contract (Month)	5 years
Operating Lease, Right-of-Use Asset	$ 1,553,611
Operating Lease, Liability, Total	$ 1,553,611
Lessee, Operating Lease, Discount Rate	12.00%
Operating Lease, Expense			68,917
Lease Agreement with Wickfield Phoenix LLC [Member] | Research and Development Expense [Member]
Operating Lease, Expense			17,229
Lease Agreement with Wickfield Phoenix LLC [Member] | General and Administrative Expense [Member]
Operating Lease, Expense			$ 51,687
Lease Agreement with Wickfield Phoenix LLC [Member] | Minimum [Member]
Monthly Rent Payment	$ 32,452
Lease Agreement with Wickfield Phoenix LLC [Member] | Maximum [Member]
Monthly Rent Payment	36,525
Lease Cancellation [Member]
Increase (Decrease) in Prepaid Rent	1,002,113
Operating Lease, Right-of-Use Asset, Lease Cancellation	1,061,210
Operating Lease, Impairment Loss	$ 59,097
Accounting Standards Update 2016-02 [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 1,613,038

Note 8 - Leases - Right of Use

Note 8 - Leases - Right of Use Asset and Lease Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Aggregate lease commitments	$ 2,067,505
Less: impact of present value	(513,894)
Balance at March 31, 2020	1,553,611
Straight line amortization	68,917
Interest	(15,212)
Balance at March 31, 2020	53,705
March 31, 2020	1,499,906	$ 1,103,658
Additions	1,553,611
Payments	(64,904)
Interest	15,212
Operating Lease, Liability, Total	1,503,919
Current portion of lease liabilities	222,795
Long term portion of lease liabilities	1,281,124
2020	292,068
2021	400,133
2022	412,137
2023	424,501
2024	437,236
2025	36,525
Total	$ 2,002,600

Note 9 - Loan Arrangements (Det

Note 9 - Loan Arrangements (Details Textual) - Loan Arrangement With Shareholder [Member] - USD ($)	Oct. 17, 2017	Mar. 31, 2020
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term (Year)	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		$ 0

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual) - USD ($)	Jun. 07, 2019	May 09, 2019	Jan. 14, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Mar. 14, 2020	Jan. 10, 2019
Preferred Stock, Shares Authorized (in shares)				20		20
Share Price (in dollars per share)							$ 0.18	$ 1.23
Payments of Stock Issuance Costs				$ 348,220	$ 593,172
Private Placement [Member]
Payments of Stock Issuance Costs			$ 465
Series 1 Preferred Shares [Member]
Preferred Stock, Shares Authorized (in shares)				20
Preferred Stock, Stated Value Per Share (in dollars per share)				$ 1,000,000
Net Sales Payments, Percentage of Sales				9.00%
Series 1 Preferred Shares [Member] | Private Placement [Member]
Preferred Stock, Value, Subscriptions		$ 12,000,000
Share Price (in dollars per share)		$ 1,000,000
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 7,000,000	$ 5,000,000
Payments of Stock Issuance Costs						$ 38,603

Note 10 - Preferred Stock - Iss

Note 10 - Preferred Stock - Issued and Outstanding Preferred Stock (Details) - USD ($)		3 Months Ended	12 Months Ended
		Mar. 31, 2020	Dec. 31, 2019
Balance, number (in shares)		12
Balance, amount		$ 11,961,397
Balance, number (in shares)		12	12
Balance, amount		$ 11,961,397	$ 11,961,397
Preferred stock, shares issued (in shares)		12	12
Balance at March 31, 2020		$ 11,961,397	$ 11,961,397
Series 1 Preferred Shares [Member]
Balance, number (in shares)		12
Balance, amount		$ 11,961,397
Stock issuance for financing, net of cost (in shares)	[1]		12
Stock issued from financing, amount	[1]		$ 11,961,397
Balance, number (in shares)		12	12
Balance, amount		$ 11,961,397	$ 11,961,397
Preferred stock, shares issued (in shares)		12	12
Balance at March 31, 2020		$ 11,961,397	$ 11,961,397
[1]	On May 9, 2019, the Company entered into subscription agreements to sell $12,000,000 of its Series 1 Preferred Shares to an accredited investor in a private placement at a purchase price of $1,000,000 per Series 1 Preferred Share; $5,000,000 of the purchase price was paid on May 9, 2019 and the remaining $7,000,000 was paid on June 7, 2019. The Company recorded $38,603 of share issuance costs as an offset to preferred stock in the year ended December 31, 2019.

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)	Feb. 14, 2020	Mar. 28, 2019	Jan. 14, 2019	Feb. 29, 2020	Dec. 31, 2018	Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Gain (Loss) on Settlement of Liabilities								$ 19,737
Research and Development Expense, Total							630,066	7,531,375	$ 7,531,375
Payments of Stock Issuance Costs							348,220	593,172
Proceeds from Issuance of Common Stock							$ 2,500,000	$ 3,000,000
Class of Warrant or Right, Issued During Period (in shares)							21,875,001
Issuance of Common Shares and Warrants, Direct Costs of Issuance						$ 348,220	$ 348,220
Adjustments to Equity, Warrant Issued
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)								9,337,529
Issuance of Common Shares and Warrants, Direct Costs of Issuance				$ 238,217			$ 238,217
Adjustments to Equity, Warrant Issued							(35,816)
Additional Paid-in Capital [Member]
Issuance of Common Shares and Warrants, Direct Costs of Issuance				110,003			110,003
Adjustments to Equity, Warrant Issued							$ 35,816
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	20,833,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.20
Class of Warrant or Right, Period Exerciseable (Month)	180 days
Warrants and Rights Outstanding, Term (Year)	5 years 182 days
Class of Warrant or Right, Issued During Period (in shares)	20,833,334
Class of Warrant or Right, Issued During Period, Value	$ 794,345
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,041,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.15
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Issued During Period (in shares)	1,041,667
Adjustments to Equity, Warrant Issued				52,496
Placement Agent Warrants [Member] | Common Stock [Member]
Adjustments to Equity, Warrant Issued				35,816
Placement Agent Warrants [Member] | Additional Paid-in Capital [Member]
Adjustments to Equity, Warrant Issued				$ 16,680
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,815,789
Proceeds from Issuance of Private Placement					$ 4,280,000
Payments of Stock Issuance Costs			$ 465
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		6,521,740
Payments of Stock Issuance Costs		$ 592,707
Proceeds from Issuance of Common Stock		$ 3,000,000
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	20,833,334
Shares Issued, Number of Common Shares Per Share (in shares)	1
Shares Issued, Price Per Share (in dollars per share)	$ 0.12
Proceeds from Issuance of Common Stock and Warrants	$ 2,500,000
Proceeds from Issuance of Common Stock	$ 1,705,655
One Creditor [Member]
Debt Conversion, Converted Instrument, Amount			$ 75,000
Common Stock, Number of Shares, Issued (in shares)			49,342
Common Stock, Value, Issued			$ 55,263
Gain (Loss) on Settlement of Liabilities			$ 19,737
Celsee [Member]
Common Stock, Number of Shares, Issued (in shares)			657,894
Common Stock, Value, Issued			$ 1,000,000
Research and Development Expense, Total			$ 736,841

Note 11 - Common Stock - Issued

Note 11 - Common Stock - Issued and Outstanding Common Shares (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020		Mar. 31, 2019
Number of common shares (in shares)	108,038,398
Stock issued for services	$ 2,500,000		$ 792,104
Stock issued from financing			$ 2,406,828
Stock issued due to exercise of options (in shares)	0		394,735
Stock issued due to exercise of options			$ 600,000
Number of common shares (in shares)	128,871,732
Common Stock [Member]
Number of common shares (in shares)	108,038,398		97,598,898
Capital stock	$ 38,566,820		$ 30,410,648
Stock issued for services (in shares)	20,833,334		707,236	[1],[2]
Stock issued for services	$ 1,705,655		$ 792,104	[1],[2]
Stock issued from financing (in shares)	20,833,334	[3]	9,337,529	[4],[5]
Stock issued from financing	$ 1,431,622	[3]	$ 6,686,828	[4],[5]
Stock issued due to exercise of options (in shares)			394,735
Stock issued due to exercise of options			$ 754,148
Number of common shares (in shares)	128,871,732		108,038,398
Capital stock	$ 39,998,442		$ 38,643,728
[1]	On January 14, 2019, the Company issued 657,894 common shares in satisfaction of $1,000,000 of all remaining milestones under a License and Supply Agreement with a third party. The Company recognized $736,841 as research and development expense, based on the value of the common stock on the date of issuance.
[2]	On January 14, 2019, the Company settled $75,000 of amounts due to a vendor by issuing 49,342 common shares valued at $55,263 at the date of issuance. The Company recorded a $19,737 gain on the settlement of liabilities.
[3]	On February 14, 2020, the Company completed a registered direct offering ("RDO") of its common shares and a simultaneous private placement of its warrants ("Series A Warrants") in a fixed combination of one common share and a Series A Warrant to purchase one common share, resulting in the sale of 20,833,334 common shares and Series A Warrants to purchase 20,833,334 common shares at a combined offering price of $0.12 per share and related Series A Warrant. Each Series A Warrant has an exercise price of $0.20 per share, is exercisable six months after issuance and has a term of 5.5 years. The Company also issued warrants to the placement agents to purchase 1,041,667 common shares at an exercise price of $0.15 per share ("Placement Agent Warrants"), which were exercisable immediately upon issuance and have a term of 5 years. In aggregate, the Company issued 20,833,334 common shares, 20,833,334 Series A Warrants in addition to 1,041,667 Placement Agent Warrants.
[4]	On January 14, 2019, the Company completed a non-brokered private placement, and issued 2,815,789 common shares. Gross proceeds of $4,280,000 were received prior to December 31, 2018.The Company recorded $465 of share issuance costs as an offset to common stock.
[5]	On March 28, 2019, the Company completed an underwritten public offering of its common stock pursuant to which the Company sold an aggregate 6,521,740 common shares for gross proceeds of $3,000,000. The Company recorded $592,707 of share issuance costs as an offset to common stock.

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($)	Mar. 14, 2020	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	5,056,000	5,056,000	5,995,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		0	394,735
Share-based Payment Arrangement, Expense		$ 155,022	$ 2,341,104
Proceeds from Stock Options Exercised			600,000
Stock Issued During Period, Value, Stock Options Exercised			$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total (in shares)		0	0
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised			$ (154,148)

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares	Mar. 31, 2020	Mar. 14, 2020	Mar. 01, 2020	Feb. 25, 2020	Jan. 23, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Number of Options, Options Outstanding (in shares)	11,991,265					11,991,265		7,040,265
Weighted Avg Exercise Price, Options Outstanding (in dollars per share)	$ 0.82					$ 0.82		$ 1.28
Stock options forfeited (in shares)			(50,000)	(5,000)	(50,000)
Weighted Avg Exercise Price, Options Forfeited (in dollars per share)			$ 1.52	$ 1.52	$ 1.52
Number of Options, Options Granted (in shares)		5,056,000				5,056,000	5,995,000
Weighted Avg Exercise Price, Options Granted (in dollars per share)		$ 0.19
Vested at March 31, 2020 (in shares)	8,199,265
Vested at March 31, 2020 (in dollars per share)	$ 1.11

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares	Mar. 31, 2020	Mar. 14, 2020	Dec. 31, 2019
Weighted Avg Exercise Price, Options Granted (in dollars per share)		$ 0.19
Number of Options, Options Outstanding (in shares)	11,991,265		7,040,265
Vested at March 31, 2020 (in shares)	8,199,265
Weighted Avg Remaining Life (in shares)	3,792,000
January 10, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.52
Number of Options, Options Outstanding (in shares)	5,390,265
Vested at March 31, 2020 (in shares)	5,390,265
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	284 days
January 10, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.52
Number of Options, Options Outstanding (in shares)	15,000
Vested at March 31, 2020 (in shares)	15,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	36 days
January 10, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.52
Number of Options, Options Outstanding (in shares)	10,000
Vested at March 31, 2020 (in shares)	10,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	36 days
January 10, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.52
Number of Options, Options Outstanding (in shares)	10,000
Vested at March 31, 2020 (in shares)	10,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	36 days
January 10, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 1.52
Number of Options, Options Outstanding (in shares)	10,000
Vested at March 31, 2020 (in shares)	10,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	36 days
August 16, 2019 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.26
Number of Options, Options Outstanding (in shares)	500,000
Vested at March 31, 2020 (in shares)	500,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
August 16, 2019 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.35
Number of Options, Options Outstanding (in shares)	100,000
Vested at March 31, 2020 (in shares)	100,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
August 16, 2019 [Member] | Options 3 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.45
Number of Options, Options Outstanding (in shares)	100,000
Vested at March 31, 2020 (in shares)	100,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
August 16, 2019 [Member] | Options 4 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.55
Number of Options, Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
Number of Vested Options (in shares)	100,000
August 16, 2019 [Member] | Option 5 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.65
Number of Options, Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
Number of Vested Options (in shares)	100,000
August 16, 2019 [Member] | Option 6 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.75
Number of Options, Options Outstanding (in shares)	100,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 142 days
Number of Vested Options (in shares)	100,000
September 16, 2019 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.43
Number of Options, Options Outstanding (in shares)	500,000
Weighted Avg Remaining Life (in shares)
Weighted Avg Remaining Life (Year)	1 year 167 days
Number of Vested Options (in shares)	500,000
March 14, 2020 [Member]
Weighted Avg Exercise Price, Options Granted (in dollars per share)	$ 0.19
Number of Options, Options Outstanding (in shares)	5,056,000
Weighted Avg Remaining Life (in shares)	3,792,000
Weighted Avg Remaining Life (Year)	4 years 350 days
Number of Vested Options (in shares)	1,264,000

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Mar. 14, 2020	Jan. 10, 2019
Volatility	87.00%	68.00%
Risk-free interest rate	0.49%	2.56%
Expected life (years) (Year)	5 years	2 years
Divedend yield	0.00%	0.00%
Common share price (in dollars per share)	$ 0.18	$ 1.23
Strike price (in dollars per share)	$ 0.19	$ 1.52

Note 13 - Warrants (Details Tex

Note 13 - Warrants (Details Textual)	Feb. 14, 2020$ / sharesshares
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	20,833,334
Warrants and Rights Outstanding, Term (Year)	5 years 182 days
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.20
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,041,667
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.15

Note 13 - Warrants - Detials of

Note 13 - Warrants - Detials of Outstanding Warrants (Details) - $ / shares	Feb. 14, 2020	Mar. 31, 2020
Warrant Issued (in shares)		21,875,001
Warrant One [Member]
Warrant, exercise price (in dollars per share)	$ 0.20
Warrant Issued (in shares)	20,833,334
Warrants, weighted average remaining life (Year)	5 years 138 days
Warrant Two [Member]
Warrant, exercise price (in dollars per share)	$ 0.15
Warrant Issued (in shares)	1,041,667
Warrants, weighted average remaining life (Year)	4 years 317 days

Note 13 - Warrants - Assumption

Note 13 - Warrants - Assumptions Used to Value Warrants at Grant Date (Details)	Mar. 31, 2020
Measurement Input, Price Volatility [Member] | Series A Warrants [Member]
Volatility	87
Measurement Input, Price Volatility [Member] | Placement Agent Warrants [Member]
Volatility	87
Measurement Input, Risk Free Interest Rate [Member] | Series A Warrants [Member]
Volatility	1.42
Measurement Input, Risk Free Interest Rate [Member] | Placement Agent Warrants [Member]
Volatility	1.42
Measurement Input, Expected Term [Member] | Series A Warrants [Member]
Volatility	5.5
Measurement Input, Expected Term [Member] | Placement Agent Warrants [Member]
Volatility	5
Measurement Input, Expected Dividend Rate [Member] | Series A Warrants [Member]
Volatility	0
Measurement Input, Expected Dividend Rate [Member] | Placement Agent Warrants [Member]
Volatility	0
Measurement Input, Offered Price [Member] | Series A Warrants [Member]
Volatility	0.12
Measurement Input, Offered Price [Member] | Placement Agent Warrants [Member]
Volatility	0.12
Measurement Input, Exercise Price [Member] | Series A Warrants [Member]
Volatility	0.2
Measurement Input, Exercise Price [Member] | Placement Agent Warrants [Member]
Volatility	0.15

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingencies (Details Textual) - USD ($)	Feb. 19, 2020	Sep. 12, 2019	Mar. 15, 2019	May 10, 2018
Qorvo Biotechnologies, LLC [Member]
Development and Supply Agreement, Contingent on Achievement of Future Milestone, First Payment, Cash Only			$ 2,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Only			3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Cash Portion			1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Second Payment, Equity Portion			$ 1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Cash Only		$ 3,000,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Cash Portion		1,500,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Third Payment, Equity Portion		$ 1,950,000
Development and Supply Agreement, Contingent on Achievement of Future Milestone, Fourth Payment, Cash Only	$ 2,000,000
Seraph Biosciences, Inc. [Member]
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Cash				$ 3,500,000
Development, Commercialization and Exclusive Distribution Agreement, Contingent on Achievement of Development Milestone, Equity				$ 3,500,000

Note 15 - Financial Instrumen_3

Note 15 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accounts Payable and Accrued Liabilities, Maturity Less Than 3 Months	$ 1,578,968	$ 2,087,525
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months		2,087,525
Accounts payable and accrued liabilities, Maturity Greater Than 1 Year
Accounts payable and accrued liabilities	1,578,968
Maturity Less Than 3 Months	1,578,968
Maturity 3 to 6 Months
Maturity 6 to 9 Months
Maturity 9 to 12 Months
Maturity Greater Than 1 Year
Due to Related Parties, Total	$ 1,578,968

Note 16 - Segmented Informati_3

Note 16 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Mar. 31, 2020	Feb. 29, 2020	Dec. 31, 2019
Assets	$ 5,034,530		$ 4,182,984
Total US property and equipment	876,760	$ 75,234	729,142
Total US right-of-use asset	1,499,906		1,103,658
Property, Plant and Equipment, Including Leased Assets	2,376,666		1,832,800
CANADA
Assets	312,420		249,929
UNITED STATES
Assets	4,722,110		3,933,055
Total US property and equipment	876,760		729,142
Total US right-of-use asset	$ 1,499,906		$ 1,103,658

Note 17 - Schedule of Expense_2

Note 17 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Research and development	$ 630,066	$ 7,531,375	$ 7,531,375
Professional fees	290,682	758,298	758,298
General and administrative	1,248,861	$ 3,212,357	3,212,357
Salaries, Bonus and Benefits [Member]
Research and development	212,143		245,307
Professional fees
General and administrative	751,389		2,972,172
Contracted Expenditures [Member]
Research and development	362,868		1,254,847
Professional fees
General and administrative
Marketing and Investor Relations [Member]
Research and development
Professional fees
General and administrative	49,552		52,509
Travel and Accommodation [Member]
Research and development	454		10,049
Professional fees
General and administrative	12,474		57,264
Insurance [Member]
Research and development	239		1,466
Professional fees
General and administrative	46,031		20,781
Office [Member]
Research and development	22,656		6,428
Professional fees
General and administrative	244,929		67,243
License Fees [Member]
Research and development			5,886,841
Professional fees
General and administrative
Consultant [Member]
Research and development	2,976		59,786
Professional fees	290,682		758,298
General and administrative
Regulatory [Member]
Research and development			20,998
Professional fees
General and administrative	88,468		24,104
Amortization, Right-of-use Asset [Member]
Research and development	17,229
Professional fees
General and administrative	56,018		5,940
Supplies [Member]
Research and development	11,501		45,653
Professional fees
General and administrative			$ 12,344

Note 19 - Loss Per Share (Detai

Note 19 - Loss Per Share (Details Textual)	3 Months Ended
	Mar. 31, 2020shares
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	11,991,265
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	21,875,001

Note 19 - Loss Per Share - Loss

Note 19 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss for the period	$ 2,450,618	$ 11,676,908
Weighted average shares - basic (in shares)	118,340,596	100,864,022
Stock options (in shares)
Warrants (in shares)
Denominator for diluted loss per share (in shares)	118,340,596	100,864,022
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.12)

Note 20 - Related Party Trans_3

Note 20 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation	$ 155,022	$ 2,341,104
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	156,536	320,647
Stock-based compensation	99,613	1,644,325
Total	$ 256,149	$ 1,964,972

Note 21 - Subsequent Events (De

Note 21 - Subsequent Events (Details Textual) - USD ($)	May 11, 2020	Apr. 20, 2020	Apr. 09, 2020	Mar. 28, 2019
Subsequent Event [Member]
Proceeds from Paycheck Protection Program Under CARES Act		$ 527,360
Subsequent Event [Member] | Series B Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			16,666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.15
Warrants and Rights Outstanding, Term (Year)			5 years
Proceeds from Warrant Exercises	$ 649,870
Class of Warrant or Right, Exercise Period (in shares)	4,333,167
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)				6,521,740
Public Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock and Warrants			$ 4,000,000
Offering Price (in dollars per share)			$ 0.12
Stock Issued During Period, Shares, New Issues (in shares)			33,333,334